BAUSCH & LOMB IS REDISTRIBUTING MANAGEMENT DUTIES AMONG FIVE TOP POSTS
This article was originally published in The Gray Sheet
Executive Summary
BAUSCH & LOMB IS REDISTRIBUTING MANAGEMENT DUTIES AMONG FIVE TOP POSTS filled by seasoned B&L execs who will report directly to Chairman Daniel Gill or other senior managers in an effort to create a "leaner, flatter reporting organization," the firm said Nov. 16. The realignment follows President Ronald Zarrella's announcement that he will be leaving the eyecare company at the end of November to join the General Motors Corporation as vice president and executive of the sales, service and marketing group of GM's North American automotive operations on Dec. 12. The position of B&L president will not be filled.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.